TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00725582
Drug: IMA-026
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04103060
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel applied topically twice daily for 6 weeks
Study: NCT04172987
Drug: EE/NGM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oral contraceptive administered orally
Study: NCT01477281
Drug: Daflon
Normalized name: Daflonex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
Study: NCT01477281
Drug: Venaflon (Diosmin and Hesperidin)
Normalized name: Veraflox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
Study: NCT02943486
Drug: Fitostimoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triticum vulgare
Study: NCT01201317
Drug: AZD2423
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tablet
Study: NCT01201317
Drug: AZD2423
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg tablet
Study: NCT01201317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00852540
Drug: Retpamulin Ointment, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
Study: NCT03781323
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours.
Study: NCT00735709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo-matching capsules
Study: NCT00789321
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 5 mg tablets placebo to amlodipine daily for 6 weeks
Study: NCT02280434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00801944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02068209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive a placebo 1 hour before outpatient hysteroscopy
Study: NCT03775070
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~* Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~* The basic anti-congestive medication will be kept as the same.~* The dosage may be titrated to a lesser dose by investigators according to the patient's condition.
Study: NCT01717690
Drug: CHG antiseptic body cleanser
Normalized name: CHG Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
Study: NCT00842270
Drug: AB1010
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg/day
Study: NCT00842270
Drug: AB1010
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,5 mg/kg/day
Study: NCT00842270
Drug: AB1010
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg/day
Study: NCT00842270
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to AB1010 dosages
Study: NCT01433159
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
Study: NCT00084240
Drug: Azithromycin/Chloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00257790
Drug: Tobramycin once a day
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03659344
Drug: Vicryl plus
Normalized name: VICRYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using vicryl sutures which coated with triclosan (antibiotic)
Study: NCT00079976
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00266708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate Placebo 35 mg weekly
Study: NCT04882371
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Chemotherapy for Breast Cancer
Study: NCT00619840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
Study: NCT02292706
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure of interest for participants who received LDV/SOF in a previous Gilead study for chronic HCV infection.
Study: NCT02292706
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure of interest for participants who received SOF/VEL in a previous Gilead study for chronic HCV infection.
Study: NCT01864057
Drug: thiamine hydrochloride 100 mg
Normalized name: thiamine hydrochloride 100 MG
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01893125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02292706
Drug: SOF/VEL/VOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure of interest for participants who received SOF/VEL/VOX in a previous Gilead study for chronic HCV infection.
Study: NCT04433585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01633983
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7.5 mg per week p.o. escalating up to 15 mg per week
Study: NCT01633983
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 7.5 mg per week per os escalating to 15 mg per week
Study: NCT02501798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo
Study: NCT03085030
Drug: Antioxidant Formula
Normalized name: Antioxidant Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant tablet will be taken by the patients
Study: NCT03085030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be taken by the patients
Study: NCT02292706
Drug: Other SOF-Based Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The other SOF-based regimens may have included the following:~* BMS-790052 (Daclatasvir) + GS-7977 (SOF) with or without RBV~* LDV/SOF + GS-9669, GS-7977 (SOF) + with or without RBV + TMC-435 (Simeprevir)~* LDV/SOF + Vedroprevir (VDV), LDV/SOF + GS-9669 (250 mg and 500 mg)~* LDV/SOF + VDV + RBV~* Simeprevir + SOF~* TMC-435 (Simeprevir) + VEL/SOF
Study: NCT02742909
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline as a placebo was administered as a continuous infusion for 24 hours
Study: NCT00292162
Drug: Aldosterone Antagonists - spironolactone
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
Study: NCT00738530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV every 2 weeks
Study: NCT00938470
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00938470
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02394951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical, matching inactive substance
Study: NCT04179461
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration
Study: NCT04179461
Drug: emollient cream
Normalized name: EMOLLIENT CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT00558259
Drug: matching placebo twice daily (BID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo BID
Study: NCT00183430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules are taken orally twice per day at 10 am and bedtime.
Study: NCT04179461
Drug: Asthma Controller Medication
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
Study: NCT03885973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk containing placebo for three weeks
Study: NCT03895801
Drug: Placebo-IFX-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously administered
Study: NCT03895801
Drug: Placebo-Glucocorticoid (Placebo-GC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered
Study: NCT03175211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT02207881
Drug: VDO gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: VDO gel
Study: NCT02207881
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo gel
Study: NCT01666379
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01000870
Drug: MNI-513-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
Study: NCT02952378
Drug: Albumins
Normalized name: lactalbumins, hydrolyzates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
Study: NCT00728611
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological water 3cc + lidocain 3cc
Study: NCT01559753
Drug: compare 8 to15 days of antibiotic treatment
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~* Ceftriaxone : 2 g OD during 3 days, then 1 g OD~* Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~* Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~* Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~* Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
Study: NCT02267356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01957410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
Study: NCT04037618
Drug: [14C]-EYP001a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drinking suspension
Study: NCT01830959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one a day
Study: NCT04256629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive oral dose of placebo
Study: NCT02669849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02719977
Drug: CX5461
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03281044
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
Study: NCT01452659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
Study: NCT01847469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01889160
Drug: AZD4721 Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-9 mg/mL liquid solution
Study: NCT01889160
Drug: AZD4721 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid solution
Study: NCT01347762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo capsule by mouth twice daily
Study: NCT02038543
Drug: Hydroxyproline and Leucine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
Study: NCT02372656
Drug: 1.2% Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
Study: NCT03018054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily administration
Study: NCT01170585
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.
Study: NCT01170585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01889160
Drug: AZD4721 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg/g liquid suspension
Study: NCT03168607
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
Study: NCT03712280
Drug: MNK6106
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram tablet of MNK6106 for oral administration
Study: NCT02021097
Drug: Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, orally, opd
Study: NCT02021097
Drug: Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, orally, opd
Study: NCT01947985
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Study: NCT02461693
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg delivered as pill; one-time dose
Study: NCT02461693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-based pill; one-time dose
Study: NCT00915070
Drug: Physiological saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion period 60 minutes
Study: NCT00945646
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instill four times two times a day
Study: NCT02285465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01066234
Drug: chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
Study: NCT01688583
Drug: Fentanyl matrix
Normalized name: FentaNYL Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
Study: NCT04315051
Drug: Cohort 1 J. Lividum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject to apply DBI-001 Gel on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails
Study: NCT01873014
Drug: chinese herbs-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: two agent per day, twice a day
Study: NCT01873014
Drug: chinese herbs-II
Approvals — FDA: no, EMA: no, PMDA: no
Description: two agent per day, twice a day
Study: NCT00187447
Drug: indomethacin (two different dosing regimens)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00733967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo capsules as control.
Study: NCT02172976
Drug: Natriumfolinate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03108482
Drug: Celecoxib (Celebrex®)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
Study: NCT03108482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
Study: NCT02051296
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RCT blinded placebo trial
Study: NCT02051296
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT blinded placebo trial
Study: NCT01893606
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00975416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given in the context of cognitive behavioral therapy
Study: NCT04206865
Drug: Standard Oral Vasodilators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion. Alternate vasodilators will include ARBs, hydralazine and isosorbide dinitrate, and ACEi
Study: NCT03750773
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject is given a Placebo capsule every 8 hours x 48 hours postoperatively for pain control.
Study: NCT02483585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once a month by subcutaneous injection
Study: NCT00527085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Study: NCT00825916
Drug: AZX100 Drug Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Study: NCT00526305
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg ,15 mg or 20 mg depending of age
Study: NCT00526305
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
Study: NCT00526305
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 day, i.v., days 1 to 15 in consolidation
Study: NCT00825916
Drug: AZX100 Drug Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Study: NCT04569214
Drug: PAZ320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
Study: NCT00825916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Study: NCT02423018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
Study: NCT03434678
Drug: Propofol+ Rocuronium+ Fentanyl + Inhalational
Normalized name: fentanyl Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.
Study: NCT02181205
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00699920
Drug: Coarsucam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
Study: NCT00392990
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)